N.Y. Methodist Urology Division Launches Clinical Trials

Staff Writer
Tuesday, October 20, 2009
New York Methodist Hospital’s Division of Urology, headed by Dr. Ivan Grunberger, is seeking qualified individuals to participate in three clinical research trials. The first of the three trials involves an injectable treatment for benign prostatic hyperplasia (BPH), the non-cancerous enlargement of the prostate. The medication (which is not FDA approved) will be injected directly into the prostate gland and each participant in the trial will be monitored for a year. The trial is open to men over the age of 45. The second trial will examine the effects of the drug fesoterodine on nighttime urinary frequency as well as general overactive bladder symptoms. Men and women over the age of 18 with overactive bladders may be eligible to participate. The third clinical research study will use high intensity focused ultrasound (HIFU) to treat low risk, localized prostate cancer. HIFU is not FDA approved for use in the U.S. This trial is open to men over the age of 50 with low risk prostate cancer. Individuals interested in participating in any of these research trials should contact the study’s coordinator, Celeste Egan, at (718) 230-1202.


Post new comment

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.